title: Statins and plaque stability.
abstract: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are now the standard of care for patients with hypercholesterolaemia. This class of inhibitors, known as 'statins', has been shown to reduce cardiovascular morbidity and mortality. Accumulating data demonstrates a variety of mechanisms in which HMG-CoA reductase inhibition benefits the cardiovascular system. This review will discuss the pharmacology, clinical trials, and mechanisms, besides lipid lowering, of statin therapy.
authors.affiliation: Mount Sinai Medical Center, Department of Cardiology, New York, NY 10129, USA. mardi.gomberg@msnyuhealth.org
authors.forename: Mardi
authors.initials: M
authors.lastname: Gomberg-Maitland
authors.forename: Valentin
authors.initials: V
authors.lastname: Fuster
authors.forename: Zahi Adel
authors.initials: ZA
authors.lastname: Fayad
authors.forename: Juan Jose
authors.initials: JJ
authors.lastname: Badimon
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
mesh_terms: D001161:Arteriosclerosis / Q000503:physiopathology / Q000517:prevention & control*; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors